Dose-escalated simultaneous integrated-boost treatment of prostate cancer patients via helical tomotherapy

Strahlentherapie und Onkologie

Volumn 188, Issue 5, 2012, Pages 410-416

  Geier, M ^a   Astner, S T ^a   Duma, M N ^a   Jacob, V ^b   Nieder, C ^c,d   Putzhammer, J ^a   Winkler, C ^a   Molls, M ^a   Geinitz, H ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c NORDLAND HOSPITAL   (Norway)

^d UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Acute toxicity; Image guided radiotherapy; Intensity modulated radiotherapy; Prostate cancer; Tomotherapy

Indexed keywords

ARTICLE; CANCER PATIENT; HISTOGRAM; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; PROSTATE CANCER; RADIATION DOSE; SIMULTANEOUS INTEGRATED BOOST INTENSITY MODULATED RADIATION THERAPY; TOMOTHERAPY; AGED; CLINICAL TRIAL; GASTROINTESTINAL TRACT; MIDDLE AGED; PROSTATE TUMOR; RADIATION EXPOSURE; RADIATION INJURY; RECTUM; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; UROGENITAL SYSTEM;

AGED; AGED, 80 AND OVER; GASTROINTESTINAL TRACT; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY, INTENSITY-MODULATED; RECTUM; TOMOGRAPHY, SPIRAL COMPUTED; UROGENITAL SYSTEM;

EID: 84862700842     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-012-0081-8     Document Type: Article

References (38)

1. Brenner DJ (2003) Hypofractionation for prostate cancer radiotherapy - what are the issues? Int J Radiat Oncol Biol Phys 57:912-914
2. De Meerleer G, Vakaet L, Meersschout S et al (2004) Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients. Int J Radiat Oncol Biol Phys 60:777-787 (Pubitemid 39311757)
3. Dearnaley DP, Sydes MR, Graham JD et al (2007) Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 8:475-487 (Pubitemid 46805903)
4. Di Muzio N, Fiorino C, Cozzarini C et al (2009) Phase I-II study of hypofractionated simultaneous integrated boost with tomotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 74:392-398
5. Dolezel M, Odrazka K, Vaculikova M et al (2010) Dose escalation in prostate radiotherapy up to 82 Gy using simultaneous integrated boost: direct comparison of acute and late toxicity with 3D-CRT 74 Gy and IMRT 78 Gy. Strahlenther Onkol 186:197-202
6. Fiorino C, Di Muzio N, Broggi S et al (2008) Evidence of limited motion of the prostate by carefully emptying the rectum as assessed by daily MVCT image guidance with helical tomotherapy. Int J Radiat Oncol Biol Phys 71:611-617
7. Fowler JF, Ritter MA, Chappell RJ, Brenner DJ (2003) What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys 56:1093-1104 (Pubitemid 36794043)
8. Geinitz H, Thamm R, Keller M et al (2011) Longitudinal study of intestinal symptoms and fecal continence in patients with conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 79:1373-1380
9. Ghadjar P, Gwerder N, Manser P et al (2010) High-dose (80 Gy) intensity-modulated radiation therapy with daily image-guidance as primary treatment for localized prostate cancer. Strahlenther Onkol 186:687-692
10. Goldner G, Dimopoulos J, Kirisits C, Potter R (2009) Moderate dose escalation in three-dimensional conformal localized prostate cancer radiotherapy: single-institutional experience in 398 patients comparing 66 Gy versus 70 Gy versus 74 Gy. Strahlenther Onkol 185:438-445
11. Guckenberger M, Flentje M (2007) Intensity-modulated radiotherapy (IMRT) of localized prostate cancer: a review and future perspectives. Strahlenther Onkol 183:57-62
12. Guckenberger M, Ok S, Polat B et al (2010) Toxicity after intensity-modulated, image-guided radiotherapy for prostate cancer. Strahlenther Onkol 186:535-543
13. Hentschel B, Oehler W, Strauss D et al (2011) Definition of the CTV prostate in CT and MRI by using CT-MRI image fusion in IMRT planning for prostate cancer. Strahlenther Onkol 187:183-190
14. Junius S, Haustermans K, Bussels B et al (2007) Hypofractionated intensity modulated irradiation for localized prostate cancer, results from a phase I/II feasibility study. Radiat Oncol 2:29
15. Kassim I, Dirkx ML, Heijmen BJ (2009) Evaluation of the dosimetric impact of non-exclusion of the rectum from the boost PTV in IMRT treatment plans for prostate cancer patients. Radiother Oncol 92:62-67
16. Keiler L, Dobbins D, Kulasekere R, Einstein D (2007) Tomotherapy for prostate adenocarcinoma: a report on acute toxicity. Radiother Oncol 84:171-176 (Pubitemid 47284533)
17. Kotte AN, Hofman P, Lagendijk JJ et al (20007) Intrafraction motion of the prostate during external-beam radiation therapy: analysis of 427 patients with implanted fiducial markers. Int J Radiat Oncol Biol Phys 69:419-425
18. Kuban DA, Tucker SL, Dong L et al (2008) Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70:67-74 (Pubitemid 350251041)
19. Kupelian PA, Willoughby TR, Reddy CA et al (2007) Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 68:1424-1430 (Pubitemid 47176809)
20. Levegrun S, Jackson A, Zelefsky MJ et al (2002) Risk group dependence of dose-response for biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer. Radiother Oncol 63:11-26 (Pubitemid 34626750)
21. Li XA, Wang JZ, Jursinic PA et al (2005) Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 61:1251-1257 (Pubitemid 40340921)
22. Lordick F, Geinitz H, Theisen J et al (2006) Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases. Int J Radiat Oncol Biol Phys 64:1295-1298
23. Martin JM, Rosewall T, Bayley A et al (2007) Phase II trial of hypofractionated image-guided intensity- modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 69:1084-1089 (Pubitemid 47625844)
24. Nickers P, Hermesse J, Deneufbourg JM et al (2010) Which alpha/beta ratio and half-time of repair are useful for predicting outcomes in prostate cancer? Radiother Oncol 97(3):462-466
25. Peeters ST, Heemsbergen WD, Koper PC et al (2006) Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24:1990-1996 (Pubitemid 46622106)
26. Pervez N, Small C, MacKenzie M et al (2010) Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 76:57-64
27. Pollack A, Hanlon AL, Horwitz EM et al (2006) Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 64:518-526 (Pubitemid 43083441)
28. Pollack A, Zagars GK, Starkschall G et al (2002) Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53:1097-1105 (Pubitemid 34787842)
29. Proust-Lima C, Taylor JM, Secher S et al (2011) Confirmation of a low alpha/beta ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics. Int J Radiat Oncol Biol Phys 79:195-201
30. Roach M 3rd, Hanks G, Thames H Jr et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965-974
31. Schwartz DJ, Sengupta S, Hillman DW et al (2007) Prediction of radial distance of extraprostatic extension from pretherapy factors. Int J Radiat Oncol Biol Phys 69:411-418 (Pubitemid 47380092)
32. Singh AK, Guion P, Sears-Crouse N et al (2007) Simultaneous integrated boost of biopsy proven, MRI defined dominant intra-prostatic lesions to 95 Gray with IMRT: early results of a phase I NCI study. Radiat Oncol 2:36
33. Soete G, Arcangeli S, De Meerleer G et al (2006) Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: report on acute toxicity. Radiother Oncol 80:78-81 (Pubitemid 44205307)
34. Wang KK, Vapiwala N, Deville C et al (2011) A study to quantify the effectiveness of daily endorectal balloon for prostate intrafraction motion management. Int J Radiat Oncol Biol Phys (in press)
35. Zelefsky MJ, Chan H, Hunt M et al (2006) Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 176:1415-1419 (Pubitemid 44307191)
36. Zelefsky MJ, Fuks Z, Hunt M et al (2002) High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53:1111-1116 (Pubitemid 34787844)
37. Zietman AL, Bae K, Slater JD et al (2010) Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol 28:1106-1111
38. Zucca S, Carau B, Solla I et al (2011) Prostate image- guided radiotherapy by megavolt cone-beam CT. Strahlenther Onkol 187:473-478